Clinical Trial Update: Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating ocrelizumab for prevention of clinical multiple sclerosis in individuals with radiologically isolated syndrome was terminated. Results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Radiologically Isolated Syndrome

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

Sponsor: Yale University | Conditions: Radiologically Isolated Syndrome, Multiple Sclerosis | Phase 4 | Status: TERMINATED | Results posted: 2024-10-09